Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Frank Stegelmann is active.

Publication


Featured researches published by Frank Stegelmann.


Journal of Immunology | 2005

Coordinate Expression of CC Chemokine Ligand 5, Granulysin, and Perforin in CD8 + T Cells Provides a Host Defense Mechanism against Mycobacterium tuberculosis

Frank Stegelmann; Max Bastian; Kay Swoboda; Rauf Bhat; Viviane Kiessler; Alan M. Krensky; Martin Roellinghoff; Robert L. Modlin; Steffen Stenger

The ability of CD8+ T cells to kill intracellular pathogens depends upon their capacity to attract infected cells as well as their secretion of cytolytic and antimicrobial effector molecules. We examined the Ag-induced expression of three immune effector molecules contained within cytoplasmic granules of human CD8+ T cells: the chemokine CCL5, the cytolytic molecule perforin, and the antimicrobial protein granulysin. Macrophages infected with virulent Mycobacterium tuberculosis triggered the expression of CCL5 in CD8+ T cells only in donors with previous exposure to the tuberculosis bacteria, not in naive donors. Functionally, CCL5 efficiently attracted M. tuberculosis-infected macrophages, but failed to exert direct antibacterial activity. Infected macrophages also triggered the expression of granulysin in CD8+ T cells, and granulysin was found to be highly active against drug-susceptible and drug-resistant M. tuberculosis clinical isolates. The vast majority of CCL5-positive cells coexpressed granulysin and perforin. Taken together, this report provides evidence that a subset of CD8+ T cells coordinately expresses CCL5, perforin and granulysin, thereby providing a host mechanism to attract M. tuberculosis-infected macrophages and kill the intracellular pathogen.


Journal of Immunology | 2012

Abelson Tyrosine Kinase Controls Phagosomal Acidification Required for Killing of Mycobacterium tuberculosis in Human Macrophages

Heiko Bruns; Frank Stegelmann; Mario Fabri; Konstanze Döhner; Ger van Zandbergen; Manfred Wagner; Mhairi A. Skinner; Robert L. Modlin; Steffen Stenger

The mechanisms that regulate the acidification of intracellular compartments are key to host defense against pathogens. In this paper, we demonstrate that Abl tyrosine kinase, a master switch for cell growth and trafficking of intracellular organelles, controls the acidification of lysosomes in human macrophages. Pharmacological inhibition by imatinib and gene silencing of Abelson (Abl) tyrosine kinase reduced the lysosomal pH in human macrophages by increasing the transcription and expression of the proton pumping enzyme vacuolar-type H+-adenosine triphosphatase. Because lysosomal acidification is required for antimicrobial activity against intracellular bacteria, we determined the effect of imatinib on the growth of the major human pathogen Mycobacterium tuberculosis. Imatinib limited the multiplication of M. tuberculosis, and growth restriction was dependent on acidification of the mycobacterial compartment. The effects of imatinib were also active in vivo because circulating monocytes from imatinib-treated leukemia patients were more acidic than monocytes from control donors. Importantly, sera from imatinib-treated patients triggered acidification and growth restriction of M. tuberculosis in macrophages. In summary, our results identify the control of phagosomal acidification as a novel function of Abl tyrosine kinase and provide evidence that the regulation occurs on the level of the vacuolar-type H+-adenosine triphosphatase. Given the efficacy of imatinib in a mouse model of tuberculosis and our finding that orally administered imatinib increased the ability of human serum to trigger growth reduction of intracellular M. tuberculosis, clinical evaluation of imatinib as a complementary therapy of tuberculosis, in particular multidrug or extremely drug-resistant disease, is warranted.


Blood | 2018

Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation

Sébastien Jacquelin; Jasmin Straube; Leanne Cooper; Therese Vu; Megan J. Bywater; Eva Baxter; Matthew Heidecker; Brad Wackrow; Amy Porter; Victoria Ling; Joanne Green; Rebecca Austin; Stephen Kazakoff; Nicola Waddell; Luke B. Hesson; John E. Pimanda; Frank Stegelmann; Lars Bullinger; Konstanze Döhner; Raajit Rampal; Dirk Heckl; Geoffrey R. Hill; Steven W. Lane

Myeloproliferative neoplasms (MPNs) are a group of blood cancers that arise following the sequential acquisition of genetic lesions in hematopoietic stem and progenitor cells (HSPCs). We identify mutational cooperation between Jak2V617F expression and Dnmt3a loss that drives progression from early-stage polycythemia vera to advanced myelofibrosis. Using in vivo, clustered regularly interspaced short palindromic repeats (CRISPR) with CRISPR-associated protein 9 (Cas9) disruption of Dnmt3a in Jak2V617F knockin HSPC, we show that Dnmt3a loss blocks the accumulation of erythroid elements and causes fibrotic infiltration within the bone marrow and spleen. Transcriptional analysis and integration with human data sets identified a core DNMT3A-driven gene-expression program shared across multiple models and contexts of Dnmt3a loss. Aberrant self-renewal and inflammatory signaling were seen in Dnmt3a-/- Jak2V617F HSPC, driven by increased chromatin accessibility at enhancer elements. These findings identify oncogenic cooperativity between Jak2V617F-driven MPN and Dnmt3a loss, leading to activation of HSPC enhancer-driven inflammatory signaling.


Blood | 2015

Limited Efficacy of Ponatinib in Myeloproliferative Neoplasms Associated with FGFR1 Fusion Genes

Sebastian Kreil; Lionel Ades; Martin Bommer; Frank Stegelmann; Mark Ethell; Anna Lübking; P. Martin; Ekkehard Eigendorff; Wolf-Karsten Hofmann; Nicholas C.P. Cross; Andreas Hochhaus; Andreas Reiter


Blood | 2014

Comparing the Prognostic Significance of Early Predictors of Survival in Chronic Myeloid Leukemia (CML) Treated with Imatinib - an Analysis of the Randomized CML-Study IV

Benjamin Hanfstein; Michael Lauseker; Rüdiger Hehlmann; Susanne Saussele; Philipp Erben; Christian Dietz; Alice Fabarius; Ulrike Proetel; Lida Kalmanti; Susanne Schnittger; Stefan W. Krause; Jörg Schubert; Hermann Einsele; Mathias Hänel; Jolanta Dengler; Christiane Falge; Lothar Kanz; Andreas Neubauer; Michael Kneba; Frank Stegelmann; Michael Pfreundschuh; Cornelius F. Waller; Karsten Spiekermann; Markus Pfirrmann; Joerg Hasford; Wolf-Karsten Hofmann; Andreas Hochhaus; Martin C. Müller


Blood | 2013

Pomalidomide In MPN–associated Myelofibrosis With Cytopenia: Results Of The Mpnsg 01-09 Study

Frank Stegelmann; Andreas Reiter; Edgar Jost; Norbert Gattermann; Holger Hebart; Cornelius F. Waller; Andreas Hochhaus; Uwe Platzbecker; Philippe Schafhausen; Igor Wolfgang Blau; Walter Verbeek; Florian H. Heidel; Martin Werner; Hans Kreipe; Cora Heiligensetzer; Silja Mack; Sabine Ostlender; Veronica Teleanu; Axel Benner; Hartmut Döhner; Martin Grießhammer; Konstanze Döhner


Blood | 2013

Comorbidity, Measured By The Charlson Index, Has No Negative Impact On Remission In Patients With Chronic Myeloid Leukemia: Results Of The Randomized CML-Study IV

Marie Paloma Krauss; Michael Lauseker; Rüdiger Hehlmann; Ulrike Proetel; Annette Schreiber; Lida Kalmanti; Benjamin Hanfstein; Hermann Einsele; Christiane Falge; Lothar Kanz; Andreas Neubauer; Michael Kneba; Frank Stegelmann; Michael Pfreundschuh; Cornelius F. Waller; Dominik Heim; Stefan W. Krause; Wolf K. Hofmann; Joerg Hasford; Andreas Hochhaus; Markus Pfirrmann; Martin C. Müller


Blood | 2016

Ruxolitinib Plus Pomalidomide in Myelofibrosis: Updated Results from the Mpnsg-0212 Trial (NCT01644110)

Frank Stegelmann; Holger Hebart; Markus Bangerter; Denise Wolleschak; Martin Griesshammer; Steffen Koschmieder; Nikolas von Bubnoff; Robert Möhle; Thomas Kindler; Andreas Hochhaus; Florian H. Heidel; Andreas Reiter; Christof Scheid; Rebecca Kirschbaum; Regina Reim; Ulrike Sutter; Katrin Vetter; Hartmut Döhner; Richard F. Schlenk; Konstanze Döhner


Blood | 2015

Long-Term Interferon-α Treatment in Essential Thrombocythemia

Frank Stegelmann; Stefanie Schauer; Rebecca Kirschbaum; Hartmut Döhner; Richard F. Schlenk; Martin Griesshammer; Konstanze Döhner


Journal of Clinical Oncology | 2017

Efficacy and safety of imatinib in CML over 10 years.

Rüdiger Hehlmann; Lida Kalmanti; Christian Dietz; Michael Lauseker; Lisa Heinrich; Ulrike Proetel; Andreas Hochhaus; Martin C. Müller; Alice Fabarius; Stefan W. Krause; Jolanta Dengler; Christiane Falge; Lothar Kanz; Frank Stegelmann; Michael Pfreundschuh; Karsten Spiekermann; Markus Pfirrmann; Susanne Saussele; Joerg Hasford

Collaboration


Dive into the Frank Stegelmann's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lothar Kanz

University of Tübingen

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge